Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis.
Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, California. Electronic address: jashinwu@hotmail.com.
Jashin J
JJ
Wu
American Medical Group Association, Alexandria, Virginia.
Christopher G
CG
Rowan
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
Judith D
JD
Bebchuk
Amgen, Center for Observational Research, Thousand Oaks, California.
Mary S
MS
Anthony
D000410:Alanine Transaminase / Q000097:blood*; D015535:Arthritis, Psoriatic / Q000097:blood / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects*; D002097:C-Reactive Protein / Q000032:analysis*; D015331:Cohort Studies; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy*; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D000410:Alanine Transaminase; D008727:Methotrexate